NCT02814565View on ClinicalTrials.gov

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

PHASE3CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

February 10, 2017

Study Completion Date

March 14, 2017

Conditions
Neck PainBack PainSpasm
Interventions
DRUG

Cyclobenzaprine HCl

Cyclobenzaprine HCl extended-release capsules

DRUG

Placebo

Cyclobenzaprine HCl extended release placebo-matching capsules

Trial Locations (10)

Unknown

Lipetsk

Saransk

Yekaterinburg

Kazan'

Moscow

Nizhny Novgorod

Novosibirsk

Saint Petersburg

Tver'

Yaroslavl

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT02814565 - Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin | Biotech Hunter | Biotech Hunter